OGT and Intelliseq GeneSpect Somatic Reporter
Clinical research solutions company OGT and genome informatics firm Intelliseq have launched the GeneSpect Somatic Reporter for use with OGT's SureSeq portfolio of next-generation sequencing (NGS) panels. Powered by Intelliseq's iFlow engine, GeneSpect Somatic Reporter presents genomic data and relevant clinical associations in an expert-informed format optimized for the needs of NGS reporting for hematological cancers, the companies said.
Personalis NeXT Personal Dx Early-Access Program
Personalis has launched an early-access program for its NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy test for detection of molecular residual disease and recurrence in cancer. The assay delivers sensitivity down to approximately 1 parts per million and allows patient-personalized ctDNA panels of up to 1,800 variants. The platform also employs a proprietary signal enhancement and noise suppression methodology. The early-access program is focused on lung cancer, breast cancer, and immunotherapy response monitoring.
NeoGenomics Neo Comprehensive - Heme Cancers, NSCLC Panel
NeoGenomics has made available two new cancer tests: Neo Comprehensive - Heme Cancers, a next-generation sequencing panel for comprehensive genomic profiling of hematologic malignancies, and the Early-stage Non-Small Cell Lung Cancer Panel, a therapy selection panel designed specifically for early-stage NSCLC patients. The firm said the NSCLC panel provides easy-to-interpret reports and a seven-day turnaround time.
Quanterix LucentAD p-Tau 217
Quanterix has launched its LucentAD p-Tau 217 lab-developed test for assessing brain amyloid pathology in patients suspected of having Alzheimer's disease. The blood-based assay uses J&J Innovative Medicine's p-Tau 217 antibodies and Quanterix's Simoa immunoassay technology.
C2N Diagnostics MTBR-tau
C2N Diagnostics has launched its research-use only MTBR-tau test, which measures the microtubule binding region of tau and is meant for the detection of the presence and burden of neurofibrillary tau tangles in the brain, a hallmark of Alzheimer's disease. The test is potentially an alternative to more invasive and expensive PET testing for tau tangles and could also be useful in non-Alzheimer's tauopathies like corticobasal degeneration, frontotemporal dementia, and progressive supranuclear palsy.
UCSC: eMerge Polygenic Risk Scores
The University of California Santa Cruz released the eMerge polygenic risk scores for eight common diseases for the human genome assembly GRCh37/hg19. The risk scores were selected by the NHGRI eMerge Project and relate to asthma, atrial fibrillation, breast cancer, coronary artery disease, hypercholesterolemia, prostate cancer, type 1 diabetes, and type 2 diabetes.
For more products and services, please visit the New Products page on our website.